Lower esophageal sphincter injection of a biocompatible polymer

Peters, Jeffrey H.; Silverman, David; Stein, Assaf

doi:10.1007/s00464-002-8861-3

Cited by 14 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We attribute this improvement to the use of a thinner needle combined with a procedure learning curve. Experimental studies with Enteryx Ò have described implantation of polymer in the mediastinum, most likely due to esophageal transfixation [15,27]. Early widespread use of Enteryx Ò in patients with GERD resulted in esophageal perforations and deaths [12,14].…”

Section: Discussionmentioning

confidence: 99%

Endoscopic augmentation of the esophagogastric junction with polymethylmethacrylate: durability, safety, and efficacy after 6 months in mini-pigs

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Endoscopic augmentation of the esophagogastric junction with polymethylmethacrylate: durability, safety, and efficacy after 6 months in mini-pigs

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Direct morphological evidence was reported in human study evaluating implants injected prior to scheduled esophagectomy. Thirty of 34 implants were correctly placed, but 4 were located either subserosally or externally to the gastroesophageal junction [5]. …”

Section: Injection Techniquesmentioning

confidence: 99%

Treatment of Gastroesophageal Reflux Disease: Endoscopic Aspects

Špičák

2007

Dig Dis

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a very common chronic disorder manifesting itself as heartburn, regurgitation, or dysphagia, possibly leading to esophagitis, Barrett’s esophagus and adenocarcinoma, and has a major impact on the patient’s quality of life. Both medical treatment and surgery are well-established methods with several limitations. Recently, three types of endoscopic methods in several modifications have been developed: (1) Radiofrequency therapy (Stretta procedure) is available both in Europe and USA and more than 5,000 patients have been treated to date. (2) Injection therapy requires the injection of bulking agents or implantation of bioprosthesis into the lower esophageal sphincter (LES) zone. Both Enteryx was withdrawn from the market in 2005, and Gatekeeper was suspended before FDA approval. (3) Suturing/plication therapy is based on the plication at the level of the LES, and most of all techniques resemble the principle of surgical treatment. Despite sophisticated technologies and promising short-term results, all these techniques are associated with inconsistencies, controversies, and relevant adverse affects. According to current practice, use of endoscopic methods is justifiable only as part of clinical trials. Many aspects, including commercial ones, will influence future developments in this area, which are difficult to predict.

show abstract